State Street
VIR icon

State Street’s Vir Biotechnology VIR Stock Holding History

State Street’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102M Buy
9,964,151
+2,823,057
+40% +$26.9M ﹤0.01% 1483
2026
Q1 		$64M Buy
7,141,094
+911,539
+15% +$7.26M ﹤0.01% 1616
2025
Q4 		$37.6M Buy
6,229,555
+988,262
+19% +$5.88M ﹤0.01% 1902
2025
Q3 		$29.9M Sell
5,241,293
-13,419
-0.3% -$68.6K ﹤0.01% 2013
2025
Q2 		$26.5M Sell
5,254,712
-472,451
-8% -$2.53M ﹤0.01% 2031
2025
Q1 		$37.1M Buy
5,727,163
+652,432
+13% +$5.8M ﹤0.01% 1803
2024
Q4 		$37.2M Sell
5,074,731
-550,802
-10% -$4.34M ﹤0.01% 1863
2024
Q3 		$42.1M Buy
5,625,533
+530,645
+10% +$4.61M ﹤0.01% 1785
2024
Q2 		$45.3M Sell
5,094,888
-1,972,733
-28% -$18.9M ﹤0.01% 1724
2024
Q1 		$71.6M Buy
7,067,621
+155,539
+2% +$1.58M ﹤0.01% 1520
2023
Q4 		$69.5M Sell
6,912,082
-261,346
-4% -$2.39M ﹤0.01% 1517
2023
Q3 		$67.2M Buy
7,173,428
+1,754,624
+32% +$25M ﹤0.01% 1428
2023
Q2 		$133M Buy
5,418,804
+34,641
+0.6% +$870K 0.01% 1035
2023
Q1 		$125M Sell
5,384,163
-92,294
-2% -$2.36M 0.01% 1040
2022
Q4 		$139M Sell
5,476,457
-353,960
-6% -$8.68M 0.01% 955
2022
Q3 		$112M Buy
5,830,417
+311,279
+6% +$7.91M 0.01% 1041
2022
Q2 		$141M Buy
5,519,138
+1,325,374
+32% +$30.9M 0.01% 948
2022
Q1 		$108M Buy
4,193,764
+1,665,657
+66% +$49.4M 0.01% 1240
2021
Q4 		$106M Buy
2,528,107
+240,241
+11% +$9.41M 0.01% 1260
2021
Q3 		$99.6M Buy
2,287,866
+135,931
+6% +$5.89M 0.01% 1263
2021
Q2 		$102M Buy
2,151,935
+273,208
+15% +$12.4M 0.01% 1274
2021
Q1 		$96.3M Sell
1,878,727
-1,056,977
-36% -$57M 0.01% 1264
2020
Q4 		$78.6M Buy
2,935,704
+2,006,874
+216% +$65.2M ﹤0.01% 1337
2020
Q3 		$31.9M Buy
928,830
+93,486
+11% +$4.02M ﹤0.01% 1757
2020
Q2 		$34.2M Buy
835,344
+708,966
+561% +$23.8M ﹤0.01% 1690
2020
Q1 		$4.33M Buy
126,378
+85,618
+210% +$2.3M ﹤0.01% 2702
2019
Q4 		$513K Buy
+40,760
New +$546K ﹤0.01% 3520

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

State Street's VIR Position: Q2 2026 in Review

State Street increased its Vir Biotechnology (VIR) stake by 40% in Q2 2026, buying an estimated $26.9M and bringing the position to 9,964,151 shares worth $102M. The position accounts for ﹤0.01% of the portfolio, ranked #1483.

State Street first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $141M in Q2 2022. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • State Street held 9,964,151 shares of Vir Biotechnology worth $102M as of Q2 2026.
  • State Street bought 2,823,057 Vir Biotechnology shares in Q2 2026, an estimated $26.9M.
  • Vir Biotechnology made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1483 holding.
  • State Street first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • State Street's Vir Biotechnology position peaked at $141M in Q2 2022.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.